Chronic kidney disease (CKD) is a well-established risk factor for cardiovascular (CV) disease because declining kidney ...
Chronic kidney disease (CKD) significantly amplifies cardiovascular (CV) risk, with CV disease remaining the leading cause of ...
The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
The report is based on the experience of a patient with recurrent retroperitoneal DDLPS and is believed to be the first reported case in which such a patient achieved a pathological complete response ...
AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care. Our top coverage from this year’s American Heart Association (AHA) 2025 Scientific ...
Tom Kim, MD, of Sound Long-Term Care Management, discusses how serious illness and care coordination set these ACO patients ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...
Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...
FLAMeS, a new convolutional neural network, enhances MS lesion segmentation accuracy using only T2-weighted FLAIR images, ...
We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback